Plasma Adiponectin Levels and Five-Year Survival After First-Ever Ischemic Stroke

Abstract

Background and Purpose— This study aimed to investigate the association between plasma adiponectin levels and 5-year survival after first-ever ischemic stroke. Methods— Plasma adiponectin measured within 24 hours after first-ever ischemic stroke was related to 5-year outcome. The Kaplan–Meier technique was applied in survival analysis, and the Cox proportional hazards model was used to evaluate the relationship between risk factors and prognosis. Results— The probabilities of death were 92.8%, 52.5%, and 10.5% ( P <0.001) for patients stratified according to tertiles of adiponectin (<4 μg/mL, 4 to 7 μg/mL, and >7 μg/mL, respectively). The relative risk of death was 8.1 (95% CI, 3.1, 24.5; P <0.001) for individuals with adiponectin levels in the lowest tertile compared with the upper tertile. Adiponectin <4 μg/mL (hazard ratio [HR], 5.2; 95% CI, 2.1, 18.4; P <0.001), score >15 in the National Institutes of Health Stroke Scale (HR, 3.6; 95% CI, 1.7, 15.9; P <0.001), and coronary heart disease (HR, 2.9; 95% CI, 1.5, 12.3; P <0.001) were independently associated with mortality. Conclusions— Low plasma adiponectin is related to an increased risk of 5-year mortality after first-ever ischemic stroke, independently of other adverse predictors.